Clinical Evaluation of the Anorexic Activity and Safety of 42-548 in Children: Report of a Clinical Trial

A double-blind study comparing the safety and efficacy of 42-548, a new, synthetic tricyclic appetite suppressant, with a placebo was started with 116 obese adolescent patients. All patients received a fixed daily dose of one tablet, one hour before the noon meal, for 12 weeks. A reduced caloric int...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pediatrics 1973-03, Vol.12 (3), p.145-149
Main Authors: Sharma, R.K., Collipp, P.J., Rezvani, I., Strimas, J., Maddaiah, V.T., Rezvani, E.
Format: Article
Language:English
Subjects:
Adolescent
Appetite Depressants - administration & dosage
Appetite Depressants - adverse effects
Appetite Depressants - therapeutic use
Blood Pressure
Body Weight
Child
Clinical Trials as Topic
Diet, Reducing
Evaluation Studies as Topic
Female
Humans
Imidazoles - therapeutic use
Indoles - therapeutic use
Male
Obesity - drug therapy
Placebos
Pulse
Skinfold Thickness
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A double-blind study comparing the safety and efficacy of 42-548, a new, synthetic tricyclic appetite suppressant, with a placebo was started with 116 obese adolescent patients. All patients received a fixed daily dose of one tablet, one hour before the noon meal, for 12 weeks. A reduced caloric intake was prescribed initially and the patients were instructed to stay on this diet. 42-548 produced an average weight loss of 18.9 lb. at the end of the study, and the placebo a loss of 11.8 lb., a statistically significant difference. The medication was relatively well tolerated.
ISSN:0009-9228
1938-2707
DOI:10.1177/000992287301200308